Stem Cell Clinic

Stem Cell Injection Therapy in New York City

By Stem Cell Treatment

In many cases of spinal or joint tissue damage, even drastic surgical procedures are not enough to repair the injury and return the body to its previous state. Stem cell injection therapy is a revolutionary technique using non-controversial Adult (non-embryonic) stem cells to regenerate damaged tissue and help the body recover naturally within weeks. Dr. Damon Noto is one of the few doctors in the New York City area performing this revolutionary procedure.

Stem cells are the cells in the body from which all specialized kinds of cells such as cartilage cells, skin cells, or bone cells are derived from. Under the right conditions, the right stem cells can develop into any kind of cell that the body needs. When a person has a significant joint or spinal injury, introducing stem cells to the injured area allows the cells to form into the exact type of cells that the body needs to regenerate damaged tissue and restore function.

Stem cell injection into the knee (New York City) is a therapy that utilizes adult stem cells, which are harvested from the patient's own body in one easy procedure. Our stem cell treatments do not use controversial embryonic stem cells derived from human fetal embryonic tissue.

Your first appointment is for an evaluation where we will determine the best way to obtain the stem cells from your body. The second office visit is for extracting the stem cells, and then doing the actual injection. Dr. Noto will inject concentrated stem cells into the joint or spinal injury either using mild sedation or local anesthesia. The total procedure time usually is under 2 hours, and you will be fully awake and able to walk out of the office when finished. You will not need to stay overnight or even visit a hospital, as the treatment is performed conveniently in our office or near by surgical center. We serve New Jersey, New York City, Long Island and the surrounding areas.

The procedure involves minimal discomfort, and recovery time is minimal. Many patients begin to notice results within six to eight weeks after only one treatment. Some patients will require two to three treatments to see full results, but New York stem cell therapy can help both athletes and non-athletes return to their pre-injury condition with a minimally invasive procedure.

Back to Treatments and Services

Minimally Invasive Disc Surgery

Regenerative Medicine

Dr. Noto interviewed on Channel 12.

SPINE & JOINT CENTER - New Jersey

Read more:
Stem Cell Injection Therapy in New York City

Woman grows a nose on her spine after experimental stem cell treatment goes awry

By Stem Cell Treatment

A female patient in the US has grown a nose on her back following a failed experimental stem cell treatment that was intended to cure her paralysis. The nose-like growth, which was producing a thick mucus-like material, has recently been removed as it was pressing painfully on herspine. If you ever needed an example of the potential perils of stem cell therapy, and just how little we actually know about the function of stem cells, this is it. Its also notable that this stem cell therapy was carried out in a developed country, as part of an approved trial (apparently unwanted growths are more common in developing nations with less stringent medical safeguards).

Eight years ago, olfactory stem cells were taken from the patients nose and implanted in her spine. The stem cells were meant to turn into nerve cells that would help repair the womans spine, curing her of paralysis. Instead, it seems they decided to do what they were originally meant to do and attempt to build a nose. Over a number of years, the nose-like growth eventually became big enough and nosy enough to cause pain and discomfort to the patient. As reported by New Scientist, surgeons removed a 3-centimetre-long growth, which was found to be mainly nasal tissue, as well as bits of bone and tiny nerve branches that had not connected with the spinal nerves. [DOI: 10.3171/2014.5.SPINE13992 - "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient"]

Your olfactory system. 1 is the olfactory bulb (the bit of your brain that processes smells); 6 is the olfactory receptors that bind to specific chemicals (odors). [Image credit: Wikipedia]

What went wrong, then? Basically, at the top of your nasal passages there is the olfactory mucosa. This region contains all of the machinery for picking up odors, and the neurons for sending all of that data off to your brains olfactory bulb for processing. Cells from this region can be easily and safely harvested, and with the correct processing they behave just like pluripotent embryonic stem cells that can develop into many other cell types. These olfactory stem cells could develop into cartilage, or mucus glands, or neurons. The researchers obviously wanted the latter, to cure the patients spinal nerve damage but seemingly they got it wrong, and thus she sprouted a second nose. Moving forward, newer olfactory stem cell treatments have an isolation stage to prevent this kind of thing from happening. [Read:The first 3D-printed human stem cells.]

Its important to note that medicine, despite being carried out primarily on humans, is still ultimately a scientific endeavor that requires a large amount of trial and error. In the western world, its very, very hard to get a stem cell therapy approved for human trials without lots of animal testing. Even then, the therapies are often only used on people who have nothing to lose. Obviously its hard to stomach news like this, and Im sure that stem cell critics will be quick to decry the Frankensteinian abomination created by these scientists. But when you think about the alternative no advanced medicine and significantly reduced lifespans for billions of people then really, such experimental treatments are nothing to sneeze at.

Read the original:
Woman grows a nose on her spine after experimental stem cell treatment goes awry

MediVet America Victorious in Vet-Stem Litigation

By Stem Cell Clinic

Nicholasville, KY (PRWEB) July 07, 2014

MediVet America Victorious in Vet-Stem Litigation

MediVet America, LLC is pleased to announce to its current and future customers a recent settlement with Vet-Stem, Inc. This decision, resulting from a lawsuit (MediVet America vs. Vet-Stem, Inc. Case # 13CV0498-WVG, United States District Court, So. District of California) was brought against Veterinary regenerative market competitor Vet-Stem (Poway, CA) and as of close of business July 1st 2014, brings an end to the dissemination of alleged misleading information by Vet-Stem.

The decision extends vindication to MediVet America as it relates to damaging and unsubstantiated claims against its patented regenerative medicine therapies for the large and small animal market. To date, over 10,000 animals have been treated with MediVets flagship product offering, adipose derived stem cell therapy. Through recent scientific efforts and support from the University of Kentucky College of Medicine as well as Nexellcom Biosciences (Lawrence, MA), MediVets system and protocols were independently validated. These studies can be found on the companys website http://www.medivet-america.com/references as well as in the prestigious peer reviewed Journal of Fluorescence, Automated Enumeration and Viability Measurement of Canine Stromal Vascular Fraction Cells Using Fluorescence-Based Image Cytometry Method. J.Fluoresc. 2014, Apr 17. Chan LL, Cohen DA, Kuksin D, Paradis BD, Qiu J.

Today, MediVet is pleased to announce a favorable out of court settlement in the case the company brought against Vet-Stem. This legal actionable measure to protect the MediVet brand was taken in response to false claims allegedly made in a 2013 research project from INCELL corporation. The research project, funded by Vet-Stem, was aimed at discrediting the MediVet technology and to disrupt MediVets growing market share in the Veterinary regenerative medicine space.

MediVet CEO, Jeremy Delk was pleased to put the matter to rest. This is a true victory, and extends credence once again to our message, that our mission is to continue to offer innovative solutions based in science to the Veterinary market. While the terms of the settlement are confidential, we can say that we are pleased, and this substantial six figure settlement reiterates we will not allow our loyal customers and future customers to be misled for commercially driven purposes. Furthermore, as leaders in this market it is our duty to continue to offer innovation and bring answers to an ever evolving technology. We will continue to innovate, and protect the right to do so in order to bring the gold standard in Regenerative Medicine to the progressive customers we serve today, tomorrow and in the future irrespective of the legal costs to do so.

MediVet America:

Based right outside of Lexington, KY, MediVet is the global leader in Veterinary regenerative medicine. As of Jan 1, 2014 MediVet is a part of Medical Australia, a strategic move to secure resources for future research and development projects. Since 2009 MediVet has offered a wide variety of autologous healing modalities for the equine and small animal market. To date over 1000 Veterinarians are certified to practice in-clinic adipose derived stem cell treatments.

For additional information, please email MediVet America at info@medivet-america.com or feel free to call us at 859-885-7111.

Read the original post:
MediVet America Victorious in Vet-Stem Litigation

Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by …

By Uncategorized

NEW YORK, July 7, 2014 /PRNewswire/ --Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company focused on developing and commercializing human pluripotent stem cell technology in the field of regenerative medicine. The company is currently conducting clinical trials for treating dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD), as well as several clinical and preclinical programs for other ocular therapies. Outside of ophthalmology, ACTC also has a preclinical development pipeline focused on autoimmune diseases, inflammatory diseases and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and other cell therapy research programs.

As the worldwide population has continued to age, so too has the need for regenerative medicine. In fact, by 2050, the number of people in the world over the age of 65 is expected to rise to 1.5 billion nearly triple the amount today. Unsurprisingly, as this demographic shift occurs over the next 35 years, health care expenditures are projected to increase rapidly as well. For example, in the US, the share of GDP devoted to healthcare is estimated to reach 34% by 2040 from about 18% just a few years ago. Considering the majority of treatments for chronic and/or life-threatening diseases that are available today only treat symptoms rather than offer a cure for the underlying cause, regenerative medicine such as the stem cell therapies being developed by ACTC are aimed at addressing this unmet and growing need.

Macular degeneration (i.e. age-related macular degeneration, or AMD) is a medical condition that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. This indication is the leading cause of blindness and visual impairment in adults over fifty years of age. Currently, it is estimated that there are approximately 30 million people worldwide who suffer from AMD ranging from early-stage to late-stage (i.e. legal blindness), with an estimated market size of around $30 billion. Further, in an article in the journal, Lancet projected that the number of people globally with AMD will be 196 million in 2020, growing to 288 million by 2040.

A full in-depth analyst report on ACTC that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-ACTC-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

See the rest here:
Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by ...

Why stem cell therapy is not available in Europe or United States of America – Video

By Uncategorized


Why stem cell therapy is not available in Europe or United States of America
In conversation with Dr Alok Sharma (MS, MCh.) Professor of Neurosurgery Head of Department, LTMG Hospital LTM Medical College, Sion, Mumbai. Explains, Why stem cell therapy is not available...

By: Neurogen Brain and Spine Institute

Read more:
Why stem cell therapy is not available in Europe or United States of America - Video

Spinal cord mass arising from neural stem cell therapy

By Uncategorized

PUBLIC RELEASE DATE:

8-Jul-2014

Contact: Jo Ann Eliason jaeliason@thejns.org 434-982-1209 Journal of Neurosurgery Publishing Group

Charlottesville, VA (July 8, 2014). A spinal mass was identified in a young woman with complete spinal cord injury 8 years after she had undergone implantation of olfactory mucosal cells in the hopes of regaining sensory and motor function. The case is reported and discussed in "Autograft-derived spinal cord mass following olfactory mucosal cell transplantation in a spinal cord injury patient. Case report," by Brian J. Dlouhy, MD, Olatilewa Awe, MD, Rajesh C. Rao, MD, Patricia A. Kirby, MD, and Patrick W. Hitchon, MD, published today online, ahead of print, in the Journal of Neurosurgery: Spine. The authors state that this is the first report of a spinal cord mass arising from spinal cord cell transplantation and neural stem cell therapy, and they caution that physicians should be vigilant in their follow-up of patients who undergo stem cell interventions.

In its natural state, the olfactory mucosa lines the roof of the nasal cavity, adjacent to the respiratory mucosa that lines the lower nasal cavity. In addition to smell receptor neurons, the olfactory mucosa contains progenitor cells (also known as adult stem cells) and olfactory ensheathing cellsboth of which have been shown to aid in the repair of the injured spinal cord in laboratory studies and in humans. The respiratory mucosa, on the other hand contains mucus-secreting goblet cells and mucus and serous fluidproducing cells.

The patient was 18 years old when she sustained a fracture dislocation at the 10th and 11th thoracic vertebral level in a motor vehicle accident. Despite surgery to stabilize the spine, the injury rendered the patient paraplegic. Three years later, in the hopes of regaining sensory and motor function in her lower limbs, the young woman underwent additional surgery at an institution outside the United States, during which an autograft of olfactory mucosa was placed in her spinal canal at the site of injury. Eight years after the experimental therapy, the woman sought medical care for mid- to lower-back pain at the University of Iowa Hospitals and Clinics. On neurological examination, she showed no sign of clinical improvement from the olfactory mucosal cell implantation, and imaging studies revealed a mass in her spinal canal pressing against the spinal cord. This mass was the source of the patient's pain.

Following surgery to remove the symptom-producing mass at the University of Iowa, a tissue analysis showed that the mass contained a small proportion of nonfunctional tiny nerve branches, whose appearance led the authors to suspect the nerve branches developed from transplanted neural stem-like cells. The tissue analysis also demonstrated that most of the mass consisted of multiple cysts lined with respiratory mucosa and underlying submucosal glands and goblet cells. Abundant mucus-like material was also found in the mass. Accumulation of this material over time produced the patient's symptoms.

The authors describe various ways of extracting olfactory mucosa cells for implantation. In this particular case, a portion of olfactory mucosa was transplanted; in other trials, olfactory ensheathing cells have been extracted from olfactory mucosa and purified prior to implantation. The authors suggest that the choice of bulk olfactory mucosa rather than purified olfactory ensheathing cells or stem cells as an autograft may lead to the development of a mass containing functional respiratory mucosal cells.

The authors point out that a rare case of spinal cord complication such as this should not discourage stem cell research and/or the transition of promising research to the clinical setting. However, the authors indicate the need for a better understanding of what can occur and urge clinicians to extend the monitoring period in patients treated with neural stem cell therapy for many years in case an adverse event such as this should arise. In summarizing the take-away message of the paper, Dr. Brian Dlouhy stated: "Exhaustive research on how transplanted cells divide, differentiate, and organize in animal models of disease, especially spinal cord injury, is critical to providing safe and effective treatments in humans."

###

See more here:
Spinal cord mass arising from neural stem cell therapy

Stem cell treatment causes nasal growth in woman's back

By Stem Cell Treatment

A woman in the US has developed a tumour-like growth eight years after a stem cell treatment to cure her paralysis failed. There have been a handful of cases of stem cell treatments causing growths but this appears to be the first in which the treatment was given at a Western hospital as part of an approved clinical trial.

At a hospital in Portugal, the unnamed woman, a US citizen, had tissue containing stem-cell-like cells taken from her nose and implanted in her spine. The hope was that these cells would develop into neural cells and help repair the nerve damage to the woman's spine. The treatment did not work far from it. Last year the woman, then 28, underwent surgery because of worsening pain at the implant site.

The surgeons removed a 3-centimetre-long growth, which was found to be mainly nasal tissue, as well as bits of bone and tiny nerve branches that had not connected with the spinal nerves.

The growth wasn't cancerous, but it was secreting a "thick copious mucus-like material", which is probably why it was pressing painfully on her spine, says Brian Dlouhy at the University of Iowa Hospitals and Clinics in Iowa City, Michigan, the neurosurgeon who removed the growth. The results of the surgery have now been published.

"It is sobering," says George Daley, a stem cell researcher at Harvard Medical School who has helped write guidelines for people considering stem cell treatments. "It speaks directly to how primitive our state of knowledge is about how cells integrate and divide and expand. "

The case shows that even when carried out at mainstream hospitals, experimental stem cell therapies can have unpredictable consequences, says Alexey Bersenev, a stem cell research analyst who blogs at Cell Trials. "We have to realise complications can also happen in a clinical trial," he says.

Stem cells have the prized ability to divide and replenish themselves, as well as turn into different types of tissues. There are several different stem cells, including ones obtained from an early embryo, aborted fetuses, and umbilical cord blood. There are many sources within adult tissues, too, including bone marrow.

While often hailed as the future of medicine, stem cells' ability to proliferate carries an inherent danger and the fear has always been that when implanted into a person they could turn cancerous.

Still, a few stem cell therapies have now been approved, such as a treatment available in India that takes stem cells from the patient's eye in order to regrow the surface of their cornea, and a US product based on other people's bone stem cells.

Many groups around the world are investigating a wide range of other applications, including treating heart attacks, blindness, Parkinson's disease and cancer. Research groups at universities and hospitals need to meet strict safety guidelines for clinical trials but some small private clinics are offering therapies to people without research or marketing approval. There is a growing number of lawsuits against such clinics and a few cases have been reported of tumours or excessive tissue growth (see "Ongoing stem cell trials" below).

Read the rest here:
Stem cell treatment causes nasal growth in woman's back

Enrile fit, vigorous enough for jailprosecutor

By Stem Cell Treatment

Senator Juan Ponce Enrile at Camp Crame on the way to the PNP Hospital. The Sandiganbayan has ordered Enriles arrest in connection with the plunder and graft cases filed by the Ombudsman. INQUIRER FILE PHOTO/ LEO SABANGAN

MANILA, PhilippinesFor the Office of the Special Prosecutor, Senator Juan Ponce Enrile need not be under hospital arrest for his plunder case because the 90-year-old lawmaker seemed healthier after his stem cell treatment.

During a hearing at the Sandiganbayan on Tuesday, prosecutor Annielyn Cabelis said Enriles motion for him to be detained at the Philippine National Police (PNP) General Hospital is unfounded and self-serving.

Cabelis told the court that even with his age and various illnesses, Enrile is still performing quite well as senator.

The prosecutor cited Enriles stem cell treatment as adding strength to the veteran lawmaker.

Hes undergone stem cell surgery, adding vigor to the accused. Its not really precarious as what they told the court, Cabelis said.

Associate Justice Samuel Martires noted the prosecutors claim that Enrile seemed stronger after the stem cell treatment.

The justice then went on to ask the prosecutor if she feels her blood pressure going up when she is arguing with her husband.

When the prosecutor said I dont fight with my husband, Martires pointed out that anxiety for persons facing a crime also affects their blood pressure.

Do you know an anxiety of a person who has a case, especially a criminal case? Do you know that the period of anxiety also affect blood pressure? Martires told the prosecutor.

Link:
Enrile fit, vigorous enough for jailprosecutor

Hue Hospital Succeeds in Treating Cancer with Stem Cell

By Stem Cell Treatment

Doctors of Hue Central Hospital have used stem cell transplantation to successfully treat a cancer patient of the last stage. The Hue Central Hospital announced on June 26 that its doctors have cured Le Thi Sau, 52, who was suffering ovarian cancer in the last stage, with stem cell transplant. The operation is the success of the scientific project Using stem cell in breast cancer and cervical cancer managed by Professor Nguyen Duy Thang, deputy head of the hospital. Adult stem cells have been used to treat certain cancers through bone marrow transplants. In this therapy, the stem cells that give rise to the different blood cells in the body are transplanted into the bone marrow of the patient, where they regenerate the blood. The project was given green light to carry out in the Hue Central Hospital by the Ministry of Science and Technology. Professor Nguyen Duy Thang said the success of this method will pave the way for next operations on breast and ovarian cancer patients. In the time ahead, the hospital continues to treat two other cancer female patients with the stem cell treatment. It is hoped that the treatment will save many cancer patients. (www.saigon-gpdaily.com.vn June 27)

See the original post:
Hue Hospital Succeeds in Treating Cancer with Stem Cell

Stem cell program – KU Medical Center

By Stem Cell Medical Center

A primary and high-priority area of interest in the CVRI involves investigation of adult stem cell biology and therapy. A growing body of evidence supports the notion that transplantation of adult stem/progenitor cells can induce cardiac repair and improve left ventricular function and structure after myocardial infarction. The stem cell program in the CVRI conducts research to identify the optimal cell for this purpose and to enhance the outcomes via modification of cells before transplantation.

The major goals of the stem cell program are:

Relevant projects:

Mesenchymal stem cell therapy for infarct repair: Mesenchymal stem cells represent a rare population of primitive cells that reside in the bone marrow and participate in organ repair following injury. Injection of these cells after myocardial infarction can repair the heart and improve left ventricular function. These studies are broadly directed at improving the outcomes of MSC therapy for cardiac repair.

Wnt11 signaling in stem cell-induced cardiac repair: Wnt11 is a member of the 'wingless' family of glycoproteins that participate in various biological processes, including cellular proliferation, differentiation, and migration during development. The goal of this project is to delineate the role of Wnt11 signaling in differentiation of adult bone marrow cells and in cardiac repair.

Pretreatment of stem cells for greater cardiac differentiation: Our laboratory has extensive experience with the induction of cellular differentiation using various defined media. The primary goal of this project is to identify biological agents that will direct differentiation of adult stem/progenitors in cardiac lineages.

Investigators, trainees, and associates:

Last modified: Apr 01, 2014

See the original post:
Stem cell program - KU Medical Center

→←